CareDx, Inc (CDNA)

Market Cap	1.06B
Revenue (ttm)	346.42M
Net Income (ttm)	62.08M
Shares Out	55.68M
EPS (ttm)	1.07
PE Ratio	17.78
Forward PE	26.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,446
Open	18.94
Previous Close	18.88
Day's Range	18.64 - 19.14
52-Week Range	13.81 - 34.84
Beta	2.18
Analysts	Buy
Price Target	30.33 (+58.71%)
Earnings Date	Jul 30, 2025

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Forecast

According to 6 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $30.33, which is an increase of 58.71% from the latest price.

Price Target

$30.33

(58.71% upside)

Analyst Consensus: Buy